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Abstract Angiomotin (Amot) is one of several identiﬁed
angiostatin receptors expressed by the endothelia of
angiogenic tissues. We have shown that a DNA vaccine
targeting Amot overcome immune tolerance and induce an
antibody response that hampers the progression of incipient
tumors. Following our observation of increased Amot
expression on tumor endothelia concomitant with the pro-
gression from pre-neoplastic lesions to full-ﬂedged carci-
noma, we evaluated the effect of anti-Amot vaccination on
clinically evident tumors. Electroporation of plasmid cod-
ing for the human Amot (pAmot) signiﬁcantly delayed the
progression both of autochthonous tumors in cancer prone
BALB-neuT and PyMT genetically engineered mice and
transplantable TUBO tumor in wild-type BALB/c mice.
The intensity of the inhibition directly correlated with the
titer of anti-Amot antibodies induced by the vaccine.
Tumor inhibition was associated with an increase of ves-
sels diameter with the formation of lacunar spaces, increase
in vessel permeability, massive tumor perivascular necrosis
and an effective epitope spreading that induces an immune
response against other tumor associated antigens. Greater
tumor vessel permeability also markedly enhances the
antitumor effect of doxorubicin. These data provide a
rationale for the development of novel anticancer treat-
ments based on anti-Amot vaccination in conjunction with
chemotherapy regimens.
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Introduction
Oncoantigens are self-molecules expressed at the tumor
site that play a signiﬁcant role in promoting tumor growth
and can be the targets of anti-tumor vaccines [1]. Cellular
[2] and DNA [3] vaccines may overcome immune toler-
ance and trigger a protective immune response against
oncoantigens overexpressed by tumor cells [4, 5]o ri n
tumor microenvironment [1]. Following vaccine-elicited
antibody and cell-mediated immune attack, oncoantigens
cannot be easily down-modulated nor negatively immu-
noedited as a consequence of their cancer-driving role [6].
However, while oncoantigen vaccines effectively and
persistently hamper the expansion of incipient tumors, their
efﬁcacy fades away when they are administered to mice
bearing advanced tumors. Their protective potential is thus
restricted to tumor prevention [5, 7].
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DOI 10.1007/s10456-012-9263-3In sharp contrast to these common ﬁndings, here we
show that a DNA vaccine against an oncoantigen expressed
by normal, but overexpressed by endothelial cells of tumor
vessels [8] also inhibits the growth of large established
clinically evident tumors.
As angiogenesis drives tumor growth, inhibition of its
underlying signalling pathways through vaccine-induced
immune response could provide a new way of intervening
with the progression of established tumors.
Induction of tumor angiogenesis is regulated by
numerous pro- and anti-angiogenic factors [9]. Angiostatin
speciﬁcally hampers endothelial cell migration and tumor
vascularisation in mouse tumor models [10]. Its anti-
migratory effects are mediated by angiomotin (Amot), one
of angiostatin receptors [11]. Amot is a membrane-asso-
ciated protein present on the endothelial cell surface of
angiogenic tissues [8] characterized by conserved coiled-
coil and carboxy termini-PDZ domains [12]. A shorter
angiomotin isoform (p80) confers a hyper-migratory and
invasive phenotype in transfected cells [13] and induces
endothelial cell migration during angiogenesis [14]. The
longer (p130) isoform localizes to tight junctions, regulates
cell shape and appears to play a role in the later phase of
angiogenesis [14].
We have shown that a DNA vaccine targeting Amot can
overcome immune tolerance and induce a signiﬁcant
antibody response that mimic the effect of angiostatin.
These antibodies inhibit endothelial cell migration, block
tumor cell- and basic ﬁbroblast growth factor-induced
angiogenesis in the matrigel plug assay and prevent growth
of transplanted tumors without impairing normal stromal or
retina vessels [8]. We now show that antibodies elicited
alter tumor vessel permeability and structure. These mul-
tifaceted effects of vaccine-induce anti-Amot antibodies
lead to inhibition of established clinically evident mam-
mary tumors, massive tumor perivascular necrosis, and an
effective tumor antigen presentation resulting in a form of
epitope spreading that induces an immune response against
other oncoantigens overexpressed by tumor cells. Greater
tumor vessel permeability also boosts the local accumula-
tion of drugs and enhances their antitumor effect. These
data provide a rationale for the development of fresh
anticancer treatments based on anti-Amot vaccination in
conjunction with chemotherapy regimens.
Materials and methods
Mice
Inbred female BALB/c mice, either wild type or over-
expressing the transforming activated rat HER-2/neu
oncogene under control of the MMTV promoter (BALB-
neuT mice) [15], were bred under speciﬁc pathogen-free
conditions by Biogem (Ariano Irpino, Italy) or at the
Molecular Biotechnology Center (Turin, Italy). Mice
overexpressing the polyoma virus middle T under control
of the MMTV promoter (PyMT) were purchased from
Jackson Laboratories (Bar Harbor, Maine). Mice were
treated in conformity with European Guidelines and poli-
cies as approved by the University of Turin Ethical
Committee.
Culture cell lines
TUBO cells, a cloned rat Her2/neu
? cell line established
from a lobular carcinoma of a BALB-neuT mouse [16],
were cultured in Dubecco’s Modiﬁed Eagle Medium sup-
plemented with GlutaMAX
TM I, D-glucose, HEPES buffer
(DMEM; Gibco, Rockville, MD), and 20% fetal bovine
serum (FBS; Sigma-Aldrich, St. Louis, MO). Mouse aortic
endothelial cells (MAE) transfected with human p80 Amot
(MAE Amot) or empty vector (MAE vector) [11] were
maintained in DMEM (Gibco) containing 10% FBS, 1%
Penicillin–Streptomycin (Sigma-Aldrich) in the presence
of 5 lg/ml Puromycin (Gibco). HMEC-1 (American Type
Culture Collection, Manassas, VA) were cultured onto EC
attachment factor (Gibco) coated tissue culture plates in
EndoGRO
TM medium (Millipore, Billerica, MA) supple-
mented with 5% FBS (Sigma) and 10 mM L-glutamine,
5 ng/ml epidermal growth factor, 1 lg/ml hydrocortisone,
0.75 U/ml heparin sulfate, 50 lg/ml ascorbic acid (all from
MiIlipore) and 1% Penicillin–Streptomycin (Sigma-
Aldrich).
Tumors
Wild type BALB/c mice were challenged subcutaneously
in the inguinal region with the lethal dose of 1 9 10
5
TUBO cells. The progression of autochthonous mammary
carcinomas in the mammary glands of both BALB-neuT
and PyMT mice and of subcutaneous TUBO tumors was
monitored weekly. Progressively growing masses with a
mean diameter of [1 mm were regarded as tumors, mea-
sured with a caliper in the two perpendicular diameters,
and the mean diameter was recorded. Progression of
tumors was monitored until tumor masses were evident in
all ten mammary glands (BALB-neuT and PyMT mice) or
until a tumor exceeded a mean diameter of 10–15 mm,
when mice were sacriﬁced for humane reasons. In a few
experiments mammary glands with tumor of progressive
stages and subcutaneous tumors of different sizes were
collected, stored in RNA later (Sigma-Aldrich) at 4C for
24 h, and then snap-frozen in liquid nitrogen and stored at
-80C until they were processed for morphological
analysis.
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123RNA extraction and quantitative real time PCR (qPCR)
Total RNA was isolated from specimens using an IKA-
Ultra-Turrax
 T8 homogenizer (IKA
-Werke, Staufen,
Germany) and TRIzol
 reagent (Invitrogen, San Diego,
CA). Genomic DNA contaminations were removed from
total RNA with the DNA-free kit (Ambion, Austin, TX).
RNAqualitywasestimatedbytheAgilent2100Bioanalyzer
(Agilent Technologies, Milan, Italy) and RNA was quanti-
ﬁed with a NanoVue Plus Spectrophotometer (GE Health-
care, Milan, Italy). Total RNA was divided into aliquots and
stored at -80C till use. To detect Amot mRNA, 1 lgo f
DNAse-treated RNA (DNA-free
TM kit) was retrotran-
scribed with RETROscript
TM reagents (Ambion) and qRT-
PCRs were carried out using gene-speciﬁc primers (Quan-
tiTect Primer Assay; Qiagen, Chatsworth, CA), SYBR
green and a 7900HT Fast Real Time PCR System (Applied
Biosystems, Milan, Italy). Quantitative normalization was
performed on the expression of beta-actin and the between-
sample relative expression levels were calculated using
the comparative delta Ct (threshold cycle number) method
(2
-DDCt) with a control sample as the reference point.
Protein preparation and immunoblotting
Total protein extracts were obtained by using a boiling
buffer containing 0.125 M Tris/HCl, pH 6.8 and 2.5%
sodium dodecyl sulphate (SDS). 50 lg proteins were sepa-
rated by SDS-PAGE and electroblotted onto polyvinylidene
ﬂuoride membranes (BioRad, Hercules, CA). Membranes
were blocked in 5% Blotto non-fat milk (Santa Cruz, CA)
Tris buffered saline (TBS)-Tween buffer (137 mM NaCl,
20 mM Tris/HCl, pH 7.6, 0.1% Tween-20) for 1 h at 37C,
then incubated with appropriate primary and secondary
antibodies in 1% milk TBS-Tween buffer, overnight at 4C
and for 1 h at room temperature respectively, and visualized
by enhanced chemiluminescence (ECL
, Amersham Bio-
sciences, Piscataway, NJ). The anti-Amot rabbit polyclonal
antibody (TLE) was raised against a peptide corresponding
to the 24 C-terminal amino acids of Amot, as previously
described [17]; anti-Vinculin, goat anti-mouse IgG HRP-
conjugated, goat anti-rabbit IgG HRP-conjugated mono-
clonal antibodies were all from Santa Cruz.
In vivo treatments
Empty pcDNA3 plasmid and plasmid coding for human p80
Amot (pAmot) were generated as previously described in
details [8]. Fifty lg of plasmid in 20 ll of 0.9% NaCl were
injected in the quadriceps muscle of anesthetized mice.
Immediately after the injection, two 25-ms trans-cutaneous
electric low voltage pulses with an amplitude of 150 V and
a 300-ms interval were administered at the injection site via
a multiple needle electrode connected to an electroporator
(Cliniporator
TM, IGEA s.r.l., Carpi, Italy). BALB-neuT and
PyMT transgenic mice were vaccinated twice at 16th–18th
and 6th–8th weeks of age, respectively. BALB/c mice
injected with a lethal dose of TUBO cells were vaccinated
when tumor mass reached 4 mm mean diameter and 7 days
after. Few mice so treated were also injected intravenously
(i.v.) once, 2 days after the second vaccination, with the
maximum tolerated dose of doxorubicin (Sigma-Aldrich)
(10 mg/kg of body weight).
Antibody response
To evaluate the presence of anti-Amot and anti-Her2/neu
(anti-neu) antibodies, sera from mice were collected 1 week
after the last vaccination and tested by ELISA. 96 well/
plates (Costar
, Sigma-Aldrich) were coated with 100 ng/
wellofrecombinanthuman-Amot(Origene,Rockville,MD)
or recombinant rat Her2/neu protein (Genway, San Diego,
CA),overnightat4C.Coatedplateswerethenblockedwith
3% non-fat milk (Santa Cruz) in TBS-Tween buffer for 2 h
at 37C. Plates were incubate with sera diluted in blocking
buffer (1:100 or 1:1,000) overnight at 4C. To remove any
non-speciﬁc antibody or excess serum protein, plates were
washed 3 times with TBS-Tween buffer. HRP-conjugated
anti-mouse IgG antibody (Sigma-Aldrich) was diluted
1:2,000 in blocking buffer and incubated for 1 h at 37C.
Plates were washed asdescribed above for 6times, followed
by the addition of chromogenic 3,30,5,50-Tetramethylbenz-
idine substrate (Sigma-Aldrich). Reaction was stopped by
addition of HCl 2 N and the optical density measured at
450 nm with a microplate reader (680XR, BioRad). Anti-
Amot and anti-neu IgG isotype titration was performed by
ELISA assay as described above using rat biotin-conjugated
anti-mouse IgG1, IgG2a, IgG2b, IgG3 (BD Pharmingen,
San Diego, CA) as secondary antibodies. Plates were then
incubated for 30 min with streptavidin-HRP (R&D Sys-
tems,Minneapolis,MN)diluted1:200inTBS-Tweenbuffer
and then reactions were carried forward as described above.
Proliferation assay
HMEC-1 cells were plated in 96-well plates at a density of
5 9 10
3 cells/well in EndoGRO
TM medium (Millipore)
with 2% FBS. After 18 h medium was removed and cell
were ﬁxed with 2.5% glutaraldehyde and stained with 0.1%
crystal violet to determine t0. Cell proliferation was then
stimulated adding fresh medium with 5% FBS. At the same
time puriﬁed IgG from sera of pAmot or pcDNA3 vacci-
nated mice were added at the concentration of 20 lg/ml.
Total IgG were puriﬁed using Melon
TM Gel IgG Spin
Puriﬁcation kit (Thermo Scientiﬁc, Milan, Italy) according
to manufacturer’s instructions. After 48 h incubation, cells
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crystal violet. The dye was solubilized using 10% acetic
acid, and optical density was measured with a Microplate
Reader 680 XR (BioRad) at 570 nm wavelength. Data are
presented as mean ± SEM of three replicates.
Dynamic contrast enhanced magnetic resonance
imaging (DCE–MRI)
Magnetic resonance (MR) images were acquired on anes-
thetized mice with an Aspect M1 MRI System (Aspect
Magnet Technologies Ltd., Netanya, Israel) working at 1
Tesla. Mice were placed supine in a solenoid Tx/Tr coil
with an inner diameter of 3.5 cm. A phantom ﬁlled with
diluted ProHance
 (Bracco Imaging SpA, Milan, Italy)
was included in the ﬁeld of view (FOV), close to each
animal, to allow correction for potential spectrometer
variation. After the scout image acquisition, a T2-weighted
(w) anatomical image was acquired with a Fast Spin Echo
sequence (TR 2500 s; TE 41 ms; number of slices 8; slice
thickness 1.5 mm; FOV 40 mm; matrix 128 9 128; four
averages; acquisition time 2 m 40 s). DCE–MRI was per-
formed using an axial T1-w, a 2D spoiled gradient echo
sequence with dynamic series was acquired with three
initial pre-contrast T1-w images and 47 dynamic post-
contrast images (TR 40 ms; TE 1.8 ms; ﬂip angle 75;
number of slices 8; slice thickness 1.5 mm; FOV 40 mm;
matrix 128 9 128; one acquisition; temporal resolution
58 s per image; total examination time 50 m). B22956/1
[18], a protein-binding contrast agent (Bracco Imaging
S.p.a.), is a Gd chelate with a low molecular weight linked
to deoxycholic acid through a ﬂexible spacer, and has a
high afﬁnity for serum proteins. The relaxivity of this
contrast agent (CA) is 27 mM
-1 s
-1 at 20 MHz in human
serum. It was injected at a dose of 0.05 mmol/kg in two
groups of mice bearing 4 mm mean diameter TUBO
tumors and vaccinated with pAmot (n = 6) or pcDNA3
(n = 3) respectively. Imaging was performed 1 day before
both the ﬁrst (MRI-pre) and the second (MRI-post)
vaccination. Raw DCE–MRI data were analyzed by an
in-house script with Matlab
 software (MathWorks, Mas-
sachusetts, USA). A common way of analyzing DCE–MRI
images is to look at the shape of the time-intensity curve in
pixels [19]. For each tumor, a region of interest (ROI) was
manually drawn over the four central slices. Each voxel
within the ROI was identiﬁed as enhancing if the signal
intensity (SI) rose three standard deviations above the
mean intensity along the ﬁrst three pre-contrast images. To
address the heterogeneous enhancement in tumours, the
enhancing volume was divided in three sub-regions using a
clustering based on k-means algorithm. An high most-
enhancing, a medium- and a low-enhancing volume were
thus identiﬁed for each tumor. Mean enhancement was
determined by averaging the SI for these volumes. After
normalization to pre-contrast SI, enhancement values were
calculated at each time point of the dynamic scan, on a
voxel-by-voxel basis according to the equation:
SIenhðtÞ ¼
SIðtÞ   SIpre

SIpre
wherein each voxel SI(t) is the SI at a given time point, SIpre
is mean of the SI for the three images before the injection of
the contrast agent. To delineate the shape of time–intensity
curves, additional parameters were calculated voxel-by-
voxel: (1) peak: the normalized peak enhancement deﬁned
as the maximal differential enhancement during the
dynamic scan; (2) time-to-peak: is the time point at which
the peak value was reached. Time-to-peak values were
reported as the scan number, each scan being ca. 60 s long,
(3) slope: is related to the enhancement increase from time
zero to time-to-peak, corresponding to the rate of uptake of
the CA (sec
-1); (4) washout: is the difference in enhance-
ment between the time-to-peak and the mean enhancement
of the ﬁve last images, it is related to the amount of CA that
extravasates from the tumor after the maximum enhance-
ment (sec
-1). Student’s t test was used to compare mean
parameter values in each tumour before and after electro-
poration with P\0.05 as the signiﬁcant cut-off.
Morphological observations
For the study of Amot expression in tumors, tumor cryo-
sections (10 lm) were prepared from frozen samples using
a Microm HM 560 cryostat. Sections were dried for 1 h
and ﬁxed in 4% paraformaldehyde for 10 min at room
temperature and subsequently permeabilized with PBS-
0.1% Triton X-100 (Sigma-Aldrich) for 5 min. Tumor
sections were blocked in 5% horse serum (Sigma-Aldrich)
and incubated with appropriate primary antibody for 1 h at
room temperature. After 1 h incubation with secondary
antibodies the sections were mounded with ﬂouromount
with DAPI (Sigma-Aldrich) and visualized using the Zeiss
700 laser scanning microscope or the Zeiss Axioplan 2
ﬂuorescence microscope. TLE was the primary anti-Amot
antibody [17]. All secondary antibodies were from
Molecular Probes (Alexa Fluor, Invitrogen).
Vessel permeability was investigated by injecting 50 nm
polymer microspheres (Duke Scientiﬁc, Palo Alto, CA)
diluted in 0.9% NaCl (Sigma-Aldrich) to a volume of 100 ll
into the tail vein 6 h before sacriﬁce. Tumors were then ﬁxed
in paraformaldehyde 1% for 1 h at 4C, rinsed several times
with PBS, inﬁltrated overnight with 30% sucrose in PBS at
4C, embedded in Optimum Cutting Temperature (OCT; Bio
Optica, Milan, Italy) compound and then frozen at -80C.
Tumor vasculature and necrosis were evaluated on tumors
ﬁxed in 10% neutralized formaldehyde solution and
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123embedded in parafﬁn, or ﬁxed in pyridoxal phosphate and
embeddedinOCT.4 lmthicksectionswerestainedwithanti-
CD31antibody(SantaCruz).Othersectionswerestainedwith
hematoxylin and eosin as previously described in detail [20].
Statistical analysis
Statistical differences were evaluated through the Graph-
Pad software 5.0 (GraphPad Inc. San Diego, CA) by using
Mantel-Cox log-rank test for the incidence of autochtho-
nous tumors in transgenic mice; Yates’s v
2 test for the
regression of transplantable tumors. All other statistical
differences were determinate with Student’s t test.
Results
Amot expression increases at later stages of cancer
progression
Amot expression evaluated by Western blot from protein
extracts of mammary glands of BALB-neuT transgenic
mice bearing foci of hyperplasia (week 6), in situ carci-
nomas (week 10), or microscopic invasive cancer (week
22), and from autochthonous carcinomas of progressive
size (from 2 to 10 mm mean diameter) (Fig. 1a), showed
that the level of Amot protein increases from pre-neoplastic
lesions to full-ﬂedged lobular carcinoma (Fig. 1a). qPCR
analysis on total RNA harvested from the same samples
showed that Amot transcript level increases until the 22nd
week (Fig. S1a), while no differences of Amot expression
were found between tumors of different size (Fig. S1a). A
similar pattern, albeit with a different kinetic was displayed
during the progression of autochthonous carcinomas of
PyMT mice (not shown). These results show that Amot
transcription and expression coincides with the angiogenic
switch characterized by burgeoning capillary sprouts that
accompanies the progression of preneoplastic lesions
towards invasive cancer [15, 21].
Amot expression levels was analyzed in in vitro cultured
TUBO cells as well as in TUBO tumors grown in BALB/c
mice (Fig. 1b, c). Even if Amot transcript was present (Fig.
S1b), Western blot analysis showed that Amot protein was
undetectable on cultured TUBO cells (Fig. 1b) while it was
Fig. 1 Amot expression on tumor endothelial cells and in vivo
tumors. Western blot of protein extracts of: a mammary glands from
BALB-neuT mice bearing foci of hyperplasia (week 6), in situ
carcinomas (week 10) and microscopic invasive cancer (week 16, 22)
and from TUBO tumors of progressive sizes (2–10 mm mean
diameter); b MAEp80 and TUBO cells cultured in vitro; c TUBO
tumors of progressive sizes. Immunoblots were probed with antibod-
ies to p80 mouse Amot (upper band, *80 kDa) and vinculin (lower
band, *100 kDa). Faint bands visible in the samples from extracts at
6, 10 and 16 weeks of age should be considered as a cross-reacting
contaminant. For each determination 3 samples were analyzed.
Immunoﬂuorescence of cryosections of 5 mm mean diameter:
d TUBO tumors growing in BALB/c mice and e autochthonous
clinically evident mammary carcinomas from BALB-neuT mice
stained with anti-CD31 (as marker of endothelial cells) and anti-Amot
antibodies
Angiogenesis (2012) 15:305–316 309
123evident in established TUBO tumors (Fig. 1c). Immuno-
ﬂuorescence analysis on cryosections of established TUBO
tumors (Fig. 1d) and autochthonous carcinomas of BALB-
neuT (Fig. 1e) and PyMT mice (Fig. S2) disclosed Amot
expression on endothelial cells of tumor vessels.
Anti-Amot vaccination hampers the growth
of autochthonous mammary carcinomas
in BALB-neuT and PyMT mice
Vaccination of BALB-neuT mice by pAmot electropora-
tion at week 16, when the angiogenic switch accompanies
the passage from in situ lesions to invasive cancer [15, 21],
signiﬁcantly extended tumor-free (Fig. 2a) and overall
survival time (Fig. 2b). At the 25th week of age, 70% of
pAmot vaccinated mice were free from palpable lesions,
while all those electroporated with the empty pcDNA3
plasmid displayed at least one palpable tumor. This result
is of special interest since in BALB-neuT mice anti-neu
vaccination affords a major and persistent protection
against incipient mammary tumors whereas it is no longer
able to extend the survival time of mice if started when
mice display multiple invasive microscopic carcinomas
(week 16) [22]. PyMT mice constitute another model of
mammary cancer. The intra-epithelial neoplasia already
evident in 6-week-old mice progresses to invasive carci-
noma by week 8–9 [23]. This progression is so aggressive
to even minimize the potential of an effective vaccine [24].
Nevertheless, pAmot vaccination at the 6th and 8th week
of age signiﬁcantly extended both tumor-free (Fig. 2d) and
overall survival time (Fig. 2e). When all mice electropo-
rated with the empty pcDNA3 plasmid displayed at least
one palpable tumor (week 15), 45% of those vaccinated
with pAmot were still free from palpable lesions. Both
BALB-neuT and PyMT mice vaccinated with pAmot
showed a high level of anti-Amot antibodies in their sera
(Fig. 2c, f).
Anti-Amot vaccination hampers the growth
of established transplantable tumors
To asses in greater detail the effect of pAmot electropor-
ation on clinically evident tumors, BALB/c mice bearing a
4 mm TUBO tumor were randomly electroporated with
pAmot or the empty pcDNA3 plasmid. While all the 28
mice electroporated with pcDNA3 homogeneously dis-
played a fast tumor progression (Fig. 3a, grey area), a
scattered and slower progression pattern was found in those
electroporated with pAmot. The time required by 4 mm
tumors to cross a 6 mm mean diameter threshold was of
Fig. 2 Effect of anti-Amot vaccination on mammary carcinogenesis
in BALB-neuT. a, b BALB-neuT and d, e PyMT mice electroporated
twice (arrows) with the pAmot (black lines, n = 12 BALB-neuT and
n = 19 PyMT mice) or pcDNA3 (dotted lines, n = 11 BALB-neuT
and n = 13 PyMT mice) plasmids. a, b P\0.0001; d P = 0.0002;
e P = 0.004 (Mantel-Cox test). Titers of anti-Amot antibodies in
BALB-neuT (c) and PyMT mice (f) vaccinated with pAmot (black
bars) or with pcDNA3 (white bars). c P = 0.008; f P\0.0001
(Student’s t test)
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1236.7 ± 0.4 days in mice electroporated with pcDNA3
compared with 13.9 ± 1.3 days for those electroporated
with pAmot (P\0.0001). The threshold of 10 mm mean
diameter was reached in 13.9 ± 0.6 days by tumors
growing in pcDNA3 electroporated mice and in
26.1 ± 1.9 days in those electroporated with pAmot
(P\0.0001). According to the time taken to reach this
threshold, pAmot electroporated mice were divided in fast
progressors, with a tumor growth pattern similar to that of
control mice (n = 14), and slow progressors when tumors
reached the 10 mm threshold after day 21 (n = 15).
Evaluation of anti-Amot antibody titers in sera collected
7 days after the last electroporation showed that slow
progressor mice are those that display the higher titer
(Fig. 3b). Puriﬁed IgG from sera of pAmot vaccinated mice
inhibit endothelial cell migration [8] and proliferation of
human endothelial cells in vitro (Fig. S3). Moreover, in
both fast and slow progressors, the anti-Amot antibodies
were mainly IgG2a and IgG2b (Fig. S4), the most active
subclasses in both complement- [25] and antibody-depen-
dent cellular cytotoxicity [26].
Anti-Amot vaccination increases tumor vessel
permeability
The above ﬁndings suggest that the induction of anti-Amot
antibodies directly correlates with the hampered growth of
the vascularized tumors. Immunoﬂuorescence analysis
performed on tumors collected 7 days after the second
pcDNA3 electroporation shows the typical irregular and
convoluted structure of the branching pattern of tumor
vessels (Fig. 4a). By contrast, increased mean vessel
Fig. 3 Effect of anti-Amot vaccination on the growth of transplan-
table TUBO tumors. BALB/c mice were challenged with TUBO cells
and electroporated with pAmot or pcDNA3 both when the TUBO
tumor reached 4 mm mean diameter and 7 days later. a Progression
of TUBO tumors: each line depicts the growth of a single tumor in
pAmot vaccinated mice (n = 29). Grey area: tumors growing in the
controls electroporated with pcDNA3 plasmid (n = 28). Data were
cumulated from three independent and concordant experiments.
b Titer of antibodies against Amot (white bars) and against neu (black
bars) in the sera of fast and low progressor mice electroporated with
pAmot and in controls electroporated with the pcDNA3 plasmid. The
titers of anti-Amot antibodies are signiﬁcantly higher in slow
progressor mice, P = 0.03 (Student’s t test)
Fig. 4 Vessel architecture, necrosis and microsphere extravasation in
TUBO tumors from pAmot vaccinated mice. Architecture of the
vascular system stained in red with anti-CD31 antibody in tumor
sections from mice electroporated with: a pcDNA3 and b pAmot
plasmids. c Typical areas of necrosis in a tumor from pcDNA3
electroporated mice and d large perivascular necrotic areas in a tumor
from pAmot electroporated mice. Extravasation of ﬂuorescent
microspheres (green spots) extravasated in the payload of perivascu-
lar space of tumors from mice: e electroporated with pcDNA3 and
f pAmot plasmids. Magniﬁcation 9200
Angiogenesis (2012) 15:305–316 311
123diameter and the formation of saccular and lacunar spaces
are dominant features of tumor vasculature in pAmot
immunized mice (Fig. 4b). A pathological evaluation of
the tumors collected 7 days after the second electropora-
tion shows that at this stage only few areas of necrosis are
evident in the TUBO tumors from pcDNA3 electroporated
mice (Fig. 4c). By contrast the saccular appearance of
vessels in tumors from pAmot immunized mice was cou-
pled with the presence of numerous and large areas of
perivascular necrosis (Fig. 4d).
We next used DCE–MRI technique to assess in vivo
whether the lacunar pattern acquired by tumor vessels and
perivascular necrosis observed following anti-Amot vac-
cination were associated with a modiﬁcation of morpho-
logic and functional characteristics of tumour vasculature.
DCE–MRI images obtained 48 h after the second electro-
poration (MRI-POST, Fig. 5a) show a higher accumulation
of the CA in the tumor area of mice vaccinated with pAmot
as compared to those electroporated with pcDNA3. This
indication of a major alteration of vessel permeability and/
or tumor perfusion following pAmot vaccination was
endorsed by a semi-quantitative assessment showing that in
pcDNA3 electroporated mice the amount of the CA in the
tumor area is less in MRI-POST than in MRI-PRE, per-
formed 1 day before vaccination (Fig. 5b), probably as the
result of the progressive disorganization of vessels that
goes along with the growth of established tumors. By
contrast, in pAmot vaccinated mice the same amount of
CA entered the tumor area in MRI-PRE and MRI-POST.
This result points to an increased vessel permeability and
ﬂuid retention follow pAmot vaccination. In the MRI-PRE
images the shape of time-intensity curves, peak enhance-
ment, the slope and the washout parameters are similar in
all mice bearing 4 mm tumors (data not shown). Despite
this homogeneous starting situation, in MRI-POST the
slope of the curve to reach the maximum enhancement
(Fig. 5c), and the peak itself (Fig. 5d) are higher in mice
electroporated with pAmot than in those electroporated
with pcDNA3 plasmid. This shows that following pAmot
vaccination the CA perfuses the tumor in signiﬁcantly
greater amount and with a faster kinetics. In addition, the
low value of the washout parameter shows that retention of
the CA in the tumor area is higher in pAmot vaccinated
mice in comparison to pcDNA3 vaccinated ones (Fig. 5e).
Studies with ﬂuorescent microspheres administered i.v.
7 days after the second electroporation (Fig. 4e, f) shows a
Fig. 5 DCE–MRI of tumor
vasculature on BALB/c mice
bearing large vascularized
TUBO tumors. a Representative
T2-w (upper panels) or T1-w
(lower panels) of MRI-POST
images of mice vaccinated with
pAmot (left panels) or pcDNA3
plasmid (right panels). b Mean
curves of MRI-PRE (dotted
lines) and MRI-POST
(continuous lines) tumor signal
intensity enhancement from
mice electroporated with pAmot
(red, n = 6) and pcDNA3
(black, n = 3). c Relative
changes of slope (sec
-1), d peak
enhancement, and e washout
(sec
-1), parameters after CA
administration in mice
electroporated with pAmot
(black bars) or pcDNA3 (white
bars). D slope P = 0.009; D
peak P = 0.007; D washout
P = 0.03 (Student’s t-test)
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123signiﬁcant microsphere extravasation and trapping in the
payload of perivascular areas of the tumors from pAmot
immunized mice (Fig. 4f). Almost no extravasation was
found in pcDNA3 electroporated mice (Fig. 4e).
Vessel alteration following anti-Amot vaccination
results in a major epitope spreading
TUBO tumors overexpress the rat Her2/neu receptor [16].
Even so, their growth in BALB/c mice does not elicit an
immune recognition of the tumor associated antigens nor a
reactive immune response [16, 27]. However, ELISA assay
showed that anti-neu antibodies were present in sera from
pAmot vaccinated mice (Fig. 3b). Interestingly, both slow
and fast progressors developed a signiﬁcant anti-neu anti-
body response, indicating that pAmot vaccination was
sufﬁcient to induce tumor antigen recognition, indepen-
dently from the titer of anti-Amot antibodies induced and
the effect on tumor growth. Also anti-neu antibodies were
mainly IgG2a and IgG2b (Fig. S3).
Vessel permeability following anti-Amot vaccination
improves chemotherapy
To assess whether the vessel alteration that follows anti-
Amot vaccination improves the efﬁcacy of a chemotherapy
drug, BALB/c mice bearing 4 mm mean diameter TUBO
tumors were electroporated twice with pAmot or pcDNA3
plasmid. Two days after the second electroporation they
received a 10 mg/kg i.v. injection of doxorubicin. The
combination of pcDNA3 electroporation and doxorubicin
does not affect tumor growth (Fig. 6). By contrast, a sig-
niﬁcant inhibition was afforded when anti-Amot vaccina-
tion was combined with the injection off doxorubicin. Four
out of seven mice showed a dramatic regression of large
tumor masses, a result never observed in mice only vac-
cinated with pAmot.
Discussion
The data reported here show that a DNA vaccination tar-
geting Amot in tumor vasculature impairs the progression
of established experimental mammary tumors.
This inhibition was observed in two distinct strains of
cancer-prone genetically engineered mice whose females
undergo mammary carcinogenesis. The aggressive pro-
gression of mammary lesions in BALB-neuT mice is dri-
ven by the activated rat HER-2/neu oncogene [28].
Atypical hyperplasia already evident in puberal BALB-
neuT mice progresses into multiple foci of invasive meta-
static cancer by week 16, when pAmot DNA vaccination
was started [28]. Even quicker evolution of mammary
lesions is driven by polyoma middle T in PyMT mice. The
hyperplastic lesion evident in the mammary glands at
4 weeks of age already progresses to the stage of early
carcinoma by week 8 [23], when these mice received the
second pAmot vaccination. The markedly delayed onset of
palpable tumors following pAmot vaccination acquires a
special signiﬁcance considering that anti-neu DNA vacci-
nation is only able to elicit a marked protection when
administered to BALB-neuT mice at the stage of multiple
in situ carcinomas, whereas its protective ability is already
marginal when it is administered at week 16 [22]. This
fading of the protection is a common ﬁnding with anti-
oncoantigen vaccines. The elicited response is effective
until the incipient tumor is formed by a limited number of
cells, while it loses its efﬁcacy against a large number of
proliferating and genetically instable tumor cells [29]. On
the other hand, the growth of an established tumor relies
on tumor ability to induce neovascularization and blood
supply. The initial stages of a mammary tumorigenesis take
advantage from the vascular tree of mammary glands,
whereas as the carcinoma enlarges its dependence from
newly formed Amot-positive capillary sprouts increases.
Moreover, reactive lymphocytes and antibodies more
readily reach their target on endothelial cells than on the
cells of an established tumor [30].
Also in PyMT mice pAmot vaccination started at week
6 and 8 of age markedly extends the time of appearance
of a palpable tumor and the overall survival. As compari-
son, in PyMT mice successful vaccination against
Fig. 6 Therapeutic effect of doxorubicin in mice vaccinated against
Amot. BALB/c mice challenged with TUBO cells were electropora-
ted with pcDNA3 or pAmot when their TUBO tumor reached 4 mm
mean diameter and then again 9 days later. Two days after the second
electroporation, a few mice received an i.v. injection of doxorubicin.
Tumor growth kinetics in mice electroporated with: pcDNA3 alone
(grey area, n = 7); pcDNA3 and injected with doxorubicin (single
black lines, n = 11); pAmot alone (orange area, n = 9); pAmot and
injected with doxorubicin (single red lines, n = 7). A marked tumor
regression was evident 4/7 (57%) of mice of the latter group.
P B 0.04 versus any other treatment group (Yates’s v
2 test)
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123alpha-lactoalbumin administered at the 6th week of age no
more than slightly reduces the size of growing tumors [24].
pAmot vaccination performed on BALB/c mice chal-
lenged with TUBO cells and bearing a fast growing, clin-
ically evident 4 mm mean diameter tumor was also still
able to markedly impair its growth in a way directly pro-
portional to the titer of vaccine-induced anti-Amot
antibodies.
This unique ability of anti-Amot vaccination to hamper
the progression of established autochthonous and trans-
plantable tumors classiﬁes Amot as a target oncoantigen of
special interest because of its restricted spatiotemporal
expression [8].
Amot overexpression was found in vessels of trans-
plantable and autochthonous experimental mammary car-
cinomas [8], in vessels of human breast tumors where it
correlates with the metastatic spreading [31] and in vessels
associated with Kaposi’s sarcoma [11]. Systemic and local
treatment with a anti-Amot monoclonal antibody prevents
pathological vessel formation associated with tumor
growth [32]. In BALB-neuT mice Amot expression in the
mammary glands becomes prominent only following the
vigorous angiogenic switch that accompanies the progres-
sion of preneoplastic lesions towards invasive cancer,
characterized by burgeoning capillary sprouts [15, 21]. In
the same way, Amot expression is not detectable in in vitro
cultured TUBO cells. However, following a TUBO cell
challenge, its expression increases at the tumor site with
the expansion of tumor-induced neovascularisation. This
restricted overexpression of Amot accounts for the absence
of autoimmune reactions affecting the vascularisation of
normal mice [8]. pAmot vaccination does not impair the
fertility of immunized female mice nor their ability to
deliver and feed newborn mice fully normal in number and
size (not shown).
We have previously shown that the immune response
that follows pAmot DNA vaccination mostly, if not com-
pletely, rests on the induction of anti-Amot antibodies [8].
This ﬁnding ﬁts in well with the direct correlation between
the titer of anti-Amot antibodies elicited by the vaccine and
the intensity of the inhibition of tumor progression we have
now observed. To tease apart the main features associated
with the inhibition of tumor progression we exploited mice
challenged with TUBO cells. First, histological analysis
showed that following pAmot vaccination tumor vessels
become larger and give rise to saccular and lacunar spaces.
This acquired vessel pattern was associated with numerous
areas of tumor perivascular necrosis. To get an assessment
of how vessel modiﬁcation following pAmot vaccination
leads to perivascular necrosis we exploited DCE–MRI, a
noninvasive technique measuring a combination of tumor
perfusion and vessel permeability [33] that is currently
used in clinical practice to detect early changes in the
tumor induced by antiangiogenic therapies [34, 35]. We
exploited the B22956/1 CA [18], a Gd-chelate with high
afﬁnity for human serum albumin in order to exploit the
contrast efﬁciency showed by this system when combined
with 1T MRI scanner [36] and the increased speciﬁcity for
the detection of vascular permeability in comparison to
small molecular weight Gd-complexes [37].
In pAmot vaccinated mice B22956/1 accumulates in the
tumor area more than in control mice, showing that tumor
vessel permeability and tumor perfusion are markedly
changed. The higher DCE–MRI values of the slope of the
curve to reach the peak enhancement and the higher peak
itself show that B22956/1 perfuses the tumor area of pA-
mot vaccinated mice better and with faster kinetics. These
ﬁndings suggesting that pAmot vaccination increases
number and dimension of tumor vessel fenestrations are
endorsed by the higher spread of ﬂuorescent microspheres
of dimensions similar to B22956/1 when bound to the
human serum albumin.
The enhanced permeability attained by tumor vessels
leads to a selective microsphere extravasation at the tumor
site and the entrapment and persistence of the CA used in
DCE–MRI in the perivascular interstitial spaces of tumor
area. Histological observation shows that these features
acquired by tumor vessels following pAmot vaccination
correlate with multiple areas of perivascular necrosis of the
tumor. Capture and processing of the dying tumor cells by
antigen presenting cells recruited in the spread areas of
perivascular necrosis account for the onset of a signiﬁcant
antibody response against neu, a major oncoantigen over-
expressed by TUBO cells [7].
An almost direct correlation among the titer of anti-
Amot antibodies induced by pAmot vaccination and the
intensity of tumor growth inhibition was evident. However,
the induction of anti-neu antibodies suggests that the
inhibition of neu
? TUBO tumors results from a synergistic
action of anti-Amot antibodies targeting tumor vasculature
and anti-neu antibodies that directly inhibit TUBO cell
proliferation [38, 39]. An improved antitumor effect may
stem from the combined reaction against endothelia and
tumor antigens [8, 40]. Nevertheless, the lack of a corre-
lation between anti-neu antibodies and the protective effect
of anti-Amot vaccination suggests a main role of anti-Amot
antibodies in the protection observed. These are mainly
IgG2a and IgG2b and thus, besides their direct effect on
endothelial cell proliferation, they can also act by recruit-
ing both complement and FccRIV expressing cells [26]t o
damage tumor vasculature.
The increased permeability acquired by tumor vessels
following pAmot vaccination also allowed an otherwise
ineffective single dose of doxorubicin to induce a delay of
tumor growth and a complete rejection of established
TUBO tumors in 4 out of 7 mice. It is well known that
314 Angiogenesis (2012) 15:305–316
123antiangiogenic drugs may improve the efﬁcacy of chemo-
therapy. Following the treatment with a humanized
monoclonal antibody neutralizing vascular endothelial
growth factor (bevacizumab) human tumors showed vessel
maturation and stabilization associated with enhanced
tumor perfusion, cytotoxic drug delivery and often pro-
longed patients survival [41]. Phase III clinical trials with
bevacizumab in combination with chemotherapy have
shown signiﬁcant improvements in progression-free and
overall survival when compared with chemotherapy alone
[42].
In conclusion, present data extend to clinical evident
tumors our previous observation on the ability of anti-
Amot vaccination to hamper tumor onset [8]. The impaired
expansion of established autochthonous and transplantable
tumors, the lacunar structure and increased permeability
acquired by tumor vessels, perivascular tumor necrosis and
the epitope spreading leading to induction of an immune
response to tumor associated antigens are multiple features
triggered by the vaccination against Amot. These not only
concur to impair the progression of established tumors, but
also make them susceptible to an otherwise poorly effec-
tive chemotherapy. These ﬁndings prospect anti-Amot
vaccination alone and in combination with conventional
chemotherapy as an attractive fresh strategy for tumor
therapy.
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